Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cue BiopharmaCUE +2.42%42 3-Year EBITDA Growth Rate is 45.10% as of Jun. 2026, which is 540% above its 10-year median of 7.05. GuruFocus rates CUE with a GF Score™ of 42/100. The stock has 3 warning signs investors should review. Among 1,130 Biotechnology companies, Cue Biopharma ranks better than 81.68% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 45.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 29.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cue Biopharma was 45.10% per year. The lowest was -174.30% per year. And the median was 7.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cue Biopharma 3-Year EBITDA Growth Rate Related Terms
CUE vs CNTB, CDXS, HURA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Cue Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 45.10% mean?
Cue Biopharma (CUE) has a 3-Year EBITDA Growth Rate of 45.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cue Biopharma and its competitors. This is 540% above median its historical median of 7.05. According to the industry distribution chart, Cue Biopharma ranks #207 out of 1130 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Cue Biopharma's 3-Year EBITDA Growth Rate too high?
Cue Biopharma's current 3-Year EBITDA Growth Rate of 45.10% is 540% above median its 10-year median of 7.05. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Cue Biopharma's value of 45.10% is 203.7% above this industry median. Based on the distribution chart, Cue Biopharma ranks #207 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cue Biopharma has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's 3-Year EBITDA Growth Rate compare to CNTB and CDXS?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #207 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Cue Biopharma in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Cue Biopharma's value of 45.10% is 203.7% above this benchmark. While the company's 10-year median is 7.05 vs. the industry median of 14.85, Cue Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current 3-Year EBITDA Growth Rate of 45.10% is 203.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cue Biopharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current 3-Year EBITDA Growth Rate is 45.10%, which is 540% above median its own 10-year median of 7.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Cue Biopharma (CUE) has a current 3-Year EBITDA Growth Rate of 45.10%. The current 3-Year EBITDA Growth Rate is 45.10%, which is 540% above median its 10-year median of 7.05 and 203.7% above the Biotechnology industry median of 14.85. Cue Biopharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cue Biopharma (CUE), the current 3-Year EBITDA Growth Rate is 45.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
42GF Score
Get the complete analysis for CUE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
